Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Deals

Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress

Fineline Cube May 19, 2025

Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...

Company

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Market Challenges

Fineline Cube May 19, 2025

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard...

Others

BMS Receives EC Approval for Opdivo-based Perioperative Regimen in NSCLC

Fineline Cube May 19, 2025

Bristol-Myers Squibb (BMS; NYSE: BMY) announced last week that it has received marketing authorization from...

Company Drug

Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial

Fineline Cube May 19, 2025

US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...

Company Drug

China’s AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US

Fineline Cube May 19, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its...

Company Drug

FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma

Fineline Cube May 16, 2025

The US Food and Drug Administration (FDA) announced this week an indication extension approval for...

Company Drug

Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease

Fineline Cube May 16, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...

Company Deals

Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership

Fineline Cube May 16, 2025

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...

Company Deals

Hainan Haiyao and Elken Global Form Five-Year Strategic Partnership in Wellness Products

Fineline Cube May 16, 2025

China-based Hainan Haiyao Co., Ltd. (SHE: 000566) has entered into a five-year strategic collaboration agreement...

Company Medical Device

Beijing Balance Medical’s Renato System Gets NMPA Approval for Valve-in-Valve Therapy

Fineline Cube May 16, 2025

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has obtained market authorization from China’s...

Company Drug

North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine

Fineline Cube May 16, 2025

China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...

Company Deals

Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss

Fineline Cube May 16, 2025

South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration...

Company

Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth

Fineline Cube May 16, 2025

Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY)...

Company Drug

CanSino Biologics Gets Indonesian Approval for Phase I Trial of Inhalable Tuberculosis Vaccine

Fineline Cube May 16, 2025

China-based CanSino Biologics Inc. (HKG: 6185), a specialist in vaccine development, has announced that it...

Company Drug

Haisco Pharma’s HSK21542 Approved by NMPA for Post-Abdominal Surgery Pain

Fineline Cube May 16, 2025

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...

Company Medical Device

Lifetech Scientific’s Aortic Arch Stent System Approved by China’s NMPA

Fineline Cube May 16, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received marketing approval from...

Company Drug

Sihuan Pharmaceutical’s Bireociclib Approved by NMPA for Advanced Breast Cancer

Fineline Cube May 16, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Drug

CANbridge’s Velaglucerase β Approved by NMPA for Gaucher’s Disease Long-Term Therapy

Fineline Cube May 16, 2025

China-based CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Merck KGaA and JD Health Launch Online Thyroid Care Center in China

Fineline Cube May 16, 2025

The Thyroid Care Center on the JD Health platform, a joint initiative between German pharmaceutical...

Company Drug

Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients

Fineline Cube May 15, 2025

Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...

Posts pagination

1 … 119 120 121 … 624

Recent updates

  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
  • Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
  • Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
  • Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Company

Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.